31
100
80
60
40
20
0
0
6
12
18
24
30
36
42
48
Median 12.7 months
(95% CI 7.8, 23.0)
Nivo 3 Q2W +
Ipi 1 Q6/12W
PFS (%)
Median 8.0 months
(95% CI 4.1, 13.2)
100
80
60
40
20
0
0
6
12
18
24
30
36
42
48
100
80
60
40
20
0
0
6
12
18
24
30
36
42
48
Median NR
(95% CI 7.8, NR)
All treated patients (n = 77)
≥1% PD-L1 (n = 46)
≥50% PD-L1 (n = 13)
Nivo 3 Q2W
Median 3.6 months
(95% CI 2.3, 6.6)
100
80
60
40
20
0
Months
0
6
12
18
24
30
36
42
48
Median 8.3 months
(95% CI 2.2, NR)
100
80
60
40
20
0
Months
0
6
12
18
24
30
36
42
48
PFS (%)
100
80
60
40
20
0
Months
0
6
12
18
24
30
36
42
48
Median 3.5 months
(95% CI 2.2, 6.6)
All treated patients (n = 52)
≥1% PD-L1 (n = 32)
≥50% PD-L1 (n = 12)
Gettinger S, et al. WCLC 2016
Nivolumab plus Ipilimumab
